This action might not be possible to undo. Are you sure you want to continue?
Fact sheet N°94 October 2011
• • • • • • Malaria is a life-threatening disease caused by parasites that are transmitted to people through the bites of infected mosquitoes. In 2009, malaria caused an estimated 781 000 deaths, mostly among African children. Malaria is preventable and curable. Increased malaria prevention and control measures are dramatically reducing the malaria burden in many places. Malaria can decrease gross domestic product by as much as 1.3% in countries with high disease rates. Non-immune travelers from malaria-free areas are very vulnerable to the disease when they get infected.
According to the World Malaria Report 2010, there were 225 million cases of malaria and an estimated 781 000 deaths in 2009, a decrease from 233 million cases and 985 000 deaths in 2000. Most deaths occur among children living in Africa where a child dies every 45 seconds of malaria and the disease accounts for approximately 20% of all childhood deaths. Malaria is caused by Plasmodium parasites. The parasites are spread to people through the bites of infected Anopheles mosquitoes, called "malaria vectors", which bite mainly between dusk and dawn. There are four types of human malaria: • Plasmodium falciparum • Plasmodium vivax • Plasmodium malariae • Plasmodium ovale. Plasmodium falciparum and Plasmodium vivax are the most common. Plasmodium falciparum is the most deadly. In recent years, some human cases of malaria have also occurred withPlasmodium knowlesi – a monkey malaria that occurs in certain forested areas of South-East Asia.
Malaria is transmitted exclusively through the bites of Anopheles mosquitoes. The intensity of transmission depends on factors related to the parasite, the vector, the human host, and the environment. About 20 different Anopheles species are locally important around the world. All of the important vector species bite at night. Anopheles mosquitoes breed in water and each species has its own breeding preference; for example some prefer shallow collections of fresh water, such as puddles, rice fields, and hoof prints. Transmission is more intense in places where the mosquito lifespan is longer (so that the parasite has time to complete its development inside the mosquito) and where it prefers to bite humans rather than other animals. For example, the long lifespan and strong human-biting habit of the African vector species is the main reason why more than 85% of the world's malaria deaths are in Africa.
falciparum malaria can progress to severe illness often leading to death. allowing asymptomatic infections to occur. or cerebral malaria. . all age groups are at risk. symptoms appear seven days or more (usually 10–15 days) after the infective mosquito bite. • semi-immune HIV-infected pregnant women in stable transmission areas. Asia. even if the patient has left the malarious area. Human immunity is another important factor. especially during first and second pregnancies. • semi-immune pregnant women in areas of high transmission. chills and vomiting – may be mild and difficult to recognize as malaria. most malaria deaths in Africa occur in young children. transmission is seasonal. In malaria endemic areas. and to a lesser extent the Middle East and parts of Europe are also affected. Immunity is developed over years of exposure. They can also occur when people with low immunity move into areas with intense malaria transmission. An estimated 200 000 infants die annually as a result of malaria infection during pregnancy. Who is at risk? Approximately half of the world's population is at risk of malaria. • immigrants from endemic areas and their children living in non-endemic areas and returning to their home countries to visit friends and relatives are similarly at risk because of waning or absent immunity. it does reduce the risk that malaria infection will cause severe disease. vivax and P. malaria was present in 108 countries and territories. Symptoms Malaria is an acute febrile illness. during all pregnancies. and while it never gives complete protection. clinical relapses may occur weeks to months after the first infection. with the peak during and just after the rainy season. In adults.malariae). For this reason. • people with HIV/AIDS. In a non-immune individual. If not treated within 24 hours. Latin America. for instance to find work. Most malaria cases and deaths occur in sub-Saharan Africa. multi-organ involvement is also frequent. especially among adults in areas of moderate or intense transmission conditions. whereas in areas with less transmission and low immunity. Specific population risk groups include: • young children in stable transmission areas who have not yet developed protective immunity against the most severe forms of the disease. The first symptoms – fever. In many places. falciparum and P. Malaria can result in miscarriage and low birth weight. or as refugees.Transmission also depends on climatic conditions that may affect the number and survival of mosquitoes. Children with severe malaria frequently develop one or more of the following symptoms: severe anaemia. However. Malaria epidemics can occur when climate and other conditions suddenly favour transmission in areas where people have little or no immunity to malaria. temperature and humidity. ovale. Women with malaria infection of the placenta also have a higher risk of passing HIV infection to their newborns. • international travellers from non-endemic areas because they lack immunity. P. such as rainfall patterns. • non-immune pregnant women as malaria causes high rates of miscarriage (up to 60% in P. headache. falciparum infection) and maternal death rates of 10–50%. In 2009. and special treatment – targeted at these liver stages – is mandatory for a complete cure. respiratory distress in relation to metabolic acidosis. For both P. These new episodes arise from "dormant" liver forms (absent in P. persons may develop partial immunity.
WHO recommends that all cases of suspected malaria be confirmed using parasite-based diagnostic testing (either microscopy or rapid diagnostic test) before giving treatment. as no alternative antimalarial medicines will be available for at least five years. WHO recommends coverage for all at-risk persons. Its full potential is realized when at least 80% of houses in targeted areas are sprayed. WHO recommends the routine monitoring of antimalarial drug resistance. More detailed recommendations are available in the Guidelines for the treatment of malaria. falciparum malaria. depending on the insecticide used and the type of surface on which it is sprayed. The best available treatment. When treated with an artemisinin-based monotherapy. undermining malaria control efforts. and in most places. Drug resistance Growing resistance to antimalarial medicines has spread very rapidly.Diagnosis and treatment Early diagnosis and treatment of malaria reduces disease and prevents deaths. If resistance to artemisinins develops and spreads to other large geographical areas. DDT can be effective for 9–12 months in . Without a second drug given as part of a combination (as is done with an ACT). Prevention Vector control is the main way to reduce malaria transmission at the community level. particularly for P. Insecticide-treated mosquito nets (ITNs) Long-lasting insecticide impregnated nets (LLINs) are the preferred form of ITNs for public health distribution programmes. patients may discontinue treatment prematurely following the rapid disappearance of malaria symptoms. Indoor spraying is effective for 3–6 months. Two forms of vector control are effective in a wide range of circumstances. so that everyone in high transmission areas sleeps under a LLIN every night. Such monotherapies are therefore one of the primary forces behind the spread of artemisinin resistance. is artemisinin-based combination therapy (ACT). For individuals personal protection against mosquito bites represents the first line of defence for malaria prevention. and supports countries to strengthen their efforts in this important area of work. It is the only intervention that can reduce malaria transmission from very high levels to close to zero. Indoor spraying with residual insecticides Indoor residual spraying (IRS) with insecticides is the most powerful way to rapidly reduce malaria transmission. as has happened before with chloroquine and sulfadoxine-pyrimethamine (SP). Treatment solely on the basis of symptoms should only be considered when a parasitological diagnosis is not possible. This results in incomplete treatment. Results of parasitological confirmation can be available in a few minutes. More comprehensive recommendations are available in the Global Plan for Artemisinin Resistance Containment (GPARC). the most cost effective way to achieve this is through provision of LLINs. these resistant parasites survive and can be passed on to a mosquito and then another person. the public health consequences could be dire. and such patients still have persistent parasites in their blood. It also contributes to reducing malaria transmission.
and coordinated efforts with partners. Longer-lasting forms of IRS insecticides are under development. and can decrease gross domestic product (GDP) by as much as 1. In recent years. although so far there have been only one or two cases of obvious control failure. For travellers. WHO recommends intermittent preventive treatment with sulfadoxine-pyrimethamine for pregnant women living in high transmission areas. Vaccines against malaria . but ultimately failed to achieve its overall goal. especially Africa. Vector control is highly dependent on the use of pyrethroids. Drugs can also be used to prevent malaria. which are the only class of insecticides used on currently recommended ITNs or LLINs. was successful in eliminating the disease in some countries. for infants living in high-transmission areas of Africa. interest in malaria eradication as a long-term goal has re-emerged. will enable more countries – particularly those where malaria transmission is low and unstable – to progress towards malaria elimination. Malaria disproportionately affects poor people who cannot afford treatment or have limited access to health care. The health costs of malaria include both personal and public expenditures on prevention and treatment. thus being abandoned less than two decades later in favour of the less ambitious goal of malaria control. Large-scale use of WHO-recommended strategies. cost-effective and safe insecticides. The choice of insecticide for IRS should always be informed by recent. 3 doses of intermittent preventive treatment with SP is recommended delivered alongside routine vaccinations. Over the long term. Currently there is a lack of alternative. local data on the susceptibility target vectors. these aggregated annual losses have resulted in substantial differences in GDP between countries with and without malaria. thereby preventing malaria disease. In some heavy-burden countries. trapping families and communities in a downward spiral of poverty. The global malaria eradication campaign. Detection of insecticide resistance should be an essential component of all national malaria control efforts to ensure that the most effective vector control methods are being used. but is an expensive and long-term endeavour. the disease accounts for: • up to 40% of public health expenditures. which suppresses the blood stage of malaria infections. The development of new. Resistance to pyrethroids has emerged. strong national commitments. • up to 60% of outpatient health clinic visits. launched by WHO in 1955. malaria can be prevented through chemoprophylaxis. Similarly. alternative insecticides is a high priority. Development of new insecticides for use on nets is a particular priority.3% in countries with high levels of transmission.some cases. • 30% to 50% of inpatient hospital admissions. Elimination Many countries – especially in temperate and sub-tropical zones – have been successful in eliminating malaria. Insecticide resistance Much of the success to date in controlling malaria is due to vector control. Economic and health system impact Malaria causes significant economic losses. particularly in Africa. during the second and third trimesters. currently available tools. however.
nongovernmental and community-based organizations.There are currently no licensed vaccines against malaria or any other human parasite. WHO is also a co-founder and host of the Roll Back Malaria partnership. and each set of results will be reviewed by external WHO advisory committees. and research and academic institutions. Other malaria vaccines are at earlier stages of research. including malaria endemic countries. and surveillance. falciparum. Results will be emerging from this trial in 3 stages. One research vaccine against P. . which is the global framework to implement coordinated action against malaria. Final results are expected in 2014 . foundations. This vaccine is currently being evaluated in a large clinical trial in 7 countries in Africa. the private sector. • developing approaches for capacity building.S/AS01. systems strengthening. is most advanced. WHO response The WHO Global Malaria Programme is responsible for charting the course for malaria control and elimination through: • forming evidence-based policy and strategy formulation. It is comprised of over 500 partners. known as RTS. development partners. • keeping independent score of global progress. The partnership mobilizes for action and resources and forges consensus among partners. • identifying threats to malaria control and elimination as well as new areas for action. A WHO recommendation for use will depend on the final results from the large clinical trial.
This action might not be possible to undo. Are you sure you want to continue?
Lo hemos llevado donde lee en su other device.
Obtenga el título completo para seguir escuchando desde donde terminó, o reinicie la previsualización.